Immunome (IMNM) Income towards Parent Company (2019 - 2026)

Immunome has reported Income towards Parent Company for 8 years, with the latest figure at -$59.3 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 32.92% year-over-year to -$59.3 million; the trailing twelve-month figure through Mar 2026 stood at -$238.8 million (down 9.48% YoY), and the FY2025 full-year result was -$224.1 million, up 26.71% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$59.3 million, up from -$72.9 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$4.5 million in Q1 2023, with the low at -$132.3 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$43.3 million across 5 years, with a median of -$44.6 million in 2025.
• Annual changes were most pronounced in 2024 — Income towards Parent Company sank 2859.05% — and 2025, when it soared 66.26%.
• Immunome's Income towards Parent Company stood at -$7.8 million in 2022, then plunged by 1115.53% to -$94.7 million in 2023, then advanced by 12.34% to -$83.0 million in 2024, then advanced by 12.18% to -$72.9 million in 2025, then climbed by 18.57% to -$59.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$59.3 million (Q1 2026), -$72.9 million (Q4 2025), and -$60.1 million (Q3 2025), per Business Quant data.